Furthermore, troglitazone and TRAIL co-treatment also decreased the cell viability and significantly sensitized apoptosis in Calu-3, HCC-15 cells (Figure 1E–1H). The gene discussed is TNFSF10; the disease is hepatocellular carcinoma.